PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
31325587-6	2019	Specifically, compared with cyclosporine/MMF as GVHD prophylaxis, the odds ratio (OR) for calcineurin inhibitor/methotrexate was .8 and for cyclosporine/prednisone .6.	Methotrexate	112-124	calcineurin binding protein 1	Homo sapiens	90-111	
30153491-0	2019	Comparative Analysis of Calcineurin Inhibitor-Based Methotrexate and Mycophenolate Mofetil-Containing Regimens for Prevention of Graft-versus-Host Disease after Reduced-Intensity Conditioning Allogeneic Transplantation.	Methotrexate	52-64	calcineurin binding protein 1	Homo sapiens	24-45	
30153491-1	2019	The combination of a calcineurin inhibitor (CNI) such as tacrolimus (TAC) or cyclosporine (CYSP) with methotrexate (MTX) or with mycophenolate mofetil (MMF) has been commonly used for graft-versus-host disease (GVHD) prophylaxis after reduced-intensity conditioning (RIC) allogeneic hematopoietic cell transplantation (alloHCT), but there are limited data comparing efficacy of the 2 regimens.	Methotrexate	102-114	calcineurin binding protein 1	Homo sapiens	21-42	
28748621-2	2018	Standard prophylaxis includes a calcineurin inhibitor (CNI) with low-dose methotrexate.	Methotrexate	74-86	calcineurin binding protein 1	Homo sapiens	55-58